RNA-Based Antipsoriatic Gene Therapy: An Updated Review Focusing on Evidence from Animal Models

References

• Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320. doi:10.1046/j.1365-2230.2001.00832.x
   PubMed Web of Science ®Google Scholar
• Wu PC, Huang IH, Wang CW, et al. New onset and exacerbations of psoriasis following COVID-19 vaccines: a systematic review. Am J Clin Dermatol. 2022;23(6):775–799. doi:10.1007/s40257-022-00721-z
   PubMed Web of Science ®Google Scholar
• Yu J, Zhao Q, Wang X, et al. Pathogenesis, multi-omics research, and clinical treatment of psoriasis. J Autoimmun. 2022;133:102916. doi:10.1016/j.jaut.2022.102916
   PubMed Web of Science ®Google Scholar
• Bakshi H, Nagpal M, Singh M, et al. Treatment of psoriasis: a comprehensive review of entire therapies. Curr Drug Saf. 2020;15(2):82–104. doi:10.2174/1574886315666200128095958
   PubMed Web of Science ®Google Scholar
• Sawarkar SP, Yadav V. Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis. Indian J Dermatol Venereol Leprol. 2021;87(3):333–340. doi:10.25259/IJDVL_470_19
   PubMed Web of Science ®Google Scholar
• Denayer T, Stöhr T, Van Roy M. Animal models in translational medicine: validation and prediction. New Horiz Transl Med. 2014;2(1):5‒11.
   PubMedGoogle Scholar
• Gangwar RS, Gudjonsson JE, Ward NL. Mouse models of psoriasis: a comprehensive review. J Invest Dermatol. 2022;142(3):884–897. doi:10.1016/j.jid.2021.06.019
   PubMed Web of Science ®Google Scholar
• Schön MP, Manzke V, Erpenbeck L. Animal models of psoriasis‒highlights and drawbacks. J Allergy Clin Immunol. 2021;147(2):439–455. doi:10.1016/j.jaci.2020.04.034
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Schön MP, Erpenbeck L. The interleukin-23/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;15(9):1323. doi:10.3389/fimmu.2018.01323
   Google Scholar
• Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54(1):102–113. doi:10.1007/s12016-018-8668-1
   PubMed Web of Science ®Google Scholar
• Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2021;184(1):14–24. doi:10.1111/bjd.19380
   PubMed Web of Science ®Google Scholar
• Fraki JE, Briggaman RA, Lazarus GS. Uninvolved skin from psoriatic patients develops signs of involved psoriatic skin after being grafted onto nude mice. Science. 1982;215(4533):685–687. doi:10.1126/science.7036342
   PubMed Web of Science ®Google Scholar
• Krueger GG, Chambers DA, Shelby J. Involved and uninvolved skin from psoriatic subjects: are they equally diseased? Assessment by skin transplanted to congenitally athymic (nude) mice. J Clin Invest. 1981;68(6):1548–1557. doi:10.1172/JCI110409
   PubMed Web of Science ®Google Scholar
• Ha HL, Wang H, Claudio E, et al. IL-20-receptor signaling delimits IL-17 production in psoriatic inflammation. J Invest Dermatol. 2020;140(1):143–151. doi:10.1016/j.jid.2019.06.127
   PubMed Web of Science ®Google Scholar
• Yadav K, Singh D, Singh MR, et al. Preclinical study models of psoriasis: state-of-The-art techniques for testing pharmaceutical products in animal and nonanimal models. Int Immunopharmacol. 2023;117:109945. doi:10.1016/j.intimp.2023.109945
   PubMed Web of Science ®Google Scholar
• Jiang W, Zhu FG, Bhagat L, et al. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol. 2013;133(7):1777–1784. doi:10.1038/jid.2013.57
   PubMed Web of Science ®Google Scholar
• Shi Z, Wu X, Rocha CS, et al. Short-term Western diet intake promotes IL-23-mediated skin and joint inflammation accompanied by changes to the gut microbiota in mice. J Invest Dermatol. 2021;141(7):1780–1791. doi:10.1016/j.jid.2020.11.032
   PubMed Web of Science ®Google Scholar
• Vinardell MP. Methodological shortcomings in the reports of the imiquimod psoriatic model. Exp Dermatol. 2022;31(3):299–303. doi:10.1111/exd.14479
   PubMed Web of Science ®Google Scholar
• Badanthadka M, Dsouza L. Imiquimod-induced psoriasis mice model: a promising tool for psoriasis research? Res J Pharm Technol. 2020;13:7.
   Google Scholar
• Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21(20):7488. doi:10.3390/ijms21207488
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–1613. doi:10.4049/jimmunol.1800013
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Dendritic cells and macrophages in the pathogenesis of psoriasis. Front Immunol. 2022;13:941071. doi:10.3389/fimmu.2022.941071
   PubMed Web of Science ®Google Scholar
• Chiang CC, Cheng WJ, Korinek M, et al. Neutrophils in psoriasis. Front Immunol. 2019;10:2376. doi:10.3389/fimmu.2019.02376
   PubMed Web of Science ®Google Scholar
• Singh R, Koppu S, Perche PO, et al. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021;22(23):12793. doi:10.3390/ijms222312793
   PubMed Web of Science ®Google Scholar
• Nedoszytko B, Szczerkowska-Dobosz A, Stawczyk-Macieja M, et al. Pathogenesis of psoriasis in the ”omic” era. Part II. Genetic, genomic and epigenetic changes in psoriasis. Postepy Dermatol Alergol. 2020;37:3.
   Web of Science ®Google Scholar
• Ray-Jones H, Eyre S, Barton A, et al. One SNP at a time: moving beyond GWAS in psoriasis. J Invest Dermatol. 2016;136(3):567–573. doi:10.1016/j.jid.2015.11.025
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Iyer MK, Stuart PE, et al. Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. Genome Biol. 2015;16(1):24. doi:10.1186/s13059-014-0570-4
   PubMedGoogle Scholar
• Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One. 2007;2(7):e610. doi:10.1371/journal.pone.0000610
   PubMed Web of Science ®Google Scholar
• Lee KY, Leung KS, Tang NLS, et al. Discovering genetic factors for psoriasis through exhaustively searching for significant second order SNP-SNP interactions. Sci Rep. 2018;8(1):15186. doi:10.1038/s41598-018-33493-w
   PubMedGoogle Scholar
• Ghafouri-Fard S, Eghtedarian R, Taheri M, et al. The eminent roles of ncRNAs in the pathogenesis of psoriasis. Noncoding RNA Res. 2020;5:3.
   Web of Science ®Google Scholar
• Schön MP. Adaptive and innate immunity in psoriasis and other inflammatory disorders. Front Immunol. 2019;10:1764. doi:10.3389/fimmu.2019.01764
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhao M, Liang G, et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J Autoimmun. 2013;41:17–24. doi:10.1016/j.jaut.2013.01.001
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–1348. doi:10.1038/ng.2467
   PubMed Web of Science ®Google Scholar
• Tang L, Liang Y, Xie H, et al. Long non-coding RNAs in cutaneous biology and proliferative skin diseases: advances and perspectives. Cell Prolif. 2020;53(1):e12698. doi:10.1111/cpr.12698
   PubMed Web of Science ®Google Scholar
• Zhu K, Li S, Liang L. MicroRNA-146a polymorphisms are associated with psoriasis vulgaris. MedRxiv. 2022;1:2.
   Google Scholar
• Shen H, Wang D, Zhan M, et al. MicroRNA‐146a and microRNA‐146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients. J Clin Lab Anal. 2022;36(2):e24198. doi:10.1002/jcla.24198
   PubMed Web of Science ®Google Scholar
• Mostafa SA, Mohammad MH, Negm WA, et al. Circulating microRNA203 and its target genes’ role in psoriasis pathogenesis. Front Med. 2022;9:988962. doi:10.3389/fmed.2022.988962
   Web of Science ®Google Scholar
• Jia HY, Zhang K, Lu WJ, et al. LncRNA MEG3 influences the proliferation and apoptosis of psoriasis epidermal cells by targeting miR-21/caspase-8. BMC Mol Cell Biol. 2019;20(1):1‒13. doi:10.1186/s12860-019-0229-9
   PubMed Web of Science ®Google Scholar
• Yan S, Xu Z, Lou F, et al. NF-κB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis. Nat Commun. 2015;6(1):7652. doi:10.1038/ncomms8652
   PubMedGoogle Scholar
• Moldovan LI, Tsoi LC, Ranjitha U, et al. Characterization of circular RNA transcriptomes in psoriasis and atopic dermatitis reveals disease-specific expression profiles. Exp Dermatol. 2021;30(8):1187–1196. doi:10.1111/exd.14227
   PubMed Web of Science ®Google Scholar
• Rakhshan A, Zarrinpour N, Moradi A, et al. A single nucleotide polymorphism within HOX Transcript Antisense RNA (HOTAIR) is associated with risk of psoriasis. Int J Immunogenet. 2020;47(5):430–434. doi:10.1111/iji.12482
   PubMed Web of Science ®Google Scholar
• Nour ZA, Elwan Y, Nassar Y, et al. Possible role of LncRNA MEG3-microRNA-21 and endoplasmic reticulum (ER) stress proteins in the pathogenesis of psoriasis vulgaris. Rep Biochem Mol Biol. 2022;11(3):367. doi:10.52547/rbmb.11.3.367
   PubMed Web of Science ®Google Scholar
• Shefler A, Patrick MT, Wasikowski R, et al. Skin-expressing lncRNAs in inflammatory responses. Front Genet. 2022;13:835740. doi:10.3389/fgene.2022.835740
   PubMed Web of Science ®Google Scholar
• Botchkareva NV. The molecular revolution in cutaneous biology: noncoding RNAs: new molecular players in dermatology and cutaneous biology. J Invest Dermatol. 2017;137(5):e105–e111. doi:10.1016/j.jid.2017.02.001
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Ståhle M, Pivarcsi A. MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol. 2008;33(3):312–315. doi:10.1111/j.1365-2230.2008.02804.x
   PubMed Web of Science ®Google Scholar
• Qiao M, Li R, Zhao X, et al. Up-regulated lncRNA-MSX2P1 promotes the growth of IL-22-stimulated keratinocytes by inhibiting miR-6731-5p and activating S100A7. Exp Cell Res. 2018;363(2):243–254. doi:10.1016/j.yexcr.2018.01.014
   PubMed Web of Science ®Google Scholar
• Rebane A, Akdis CA. MicroRNAs: essential players in the regulation of inflammation. J Allergy Clin Immunol. 2013;132(1):15–26. doi:10.1016/j.jaci.2013.04.011
   PubMed Web of Science ®Google Scholar
• Lee WR, Chou WL, Lin ZC, et al. Laser-assisted nanocarrier delivery to achieve cutaneous siRNA targeting for attenuating psoriasiform dermatitis. J Control Release. 2022;347:590–606. doi:10.1016/j.jconrel.2022.05.032
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–531. doi:10.1038/nrg1379
   PubMed Web of Science ®Google Scholar
• Hanna E, Rémuzat C, Auquier P, et al. Gene therapies development: slow progress and promising prospect. J Mark Access Health Policy. 2017;5(1):1265293. doi:10.1080/20016689.2017.1265293
   PubMedGoogle Scholar
• Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003;9(1):40–46. doi:10.1038/nm804
   PubMed Web of Science ®Google Scholar
• Li J, Li X, Zhang Y, et al. Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. J Gene Med. 2010;12(6):481–490. doi:10.1002/jgm.1459
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Liu CY, et al. A novel transdermal plasmid-dimethylsulfoxide delivery technique for treatment of psoriasis. Dermatology. 2010;221(1):84–92. doi:10.1159/000314154
   PubMed Web of Science ®Google Scholar
• Chang T, Sun L, Wang Y, et al. Inhibition of keratin 17 expression with antisense and RNAi strategies: exploring novel therapy for psoriasis. Exp Dermatol. 2011;20(7):555–560. doi:10.1111/j.1600-0625.2010.01235.x
   PubMed Web of Science ®Google Scholar
• Zibert JR, Wallbrecht K, Schön M, et al. Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. J Clin Invest. 2011;121(1):410–421. doi:10.1172/JCI41295
   PubMed Web of Science ®Google Scholar
• Guinea-Viniegra J, Jiménez M, Schonthaler HB, et al. Targeting miR-21 to treat psoriasis. Sci Transl Med. 2014;6(225):225re1. doi:10.1126/scitranslmed.3008089
   PubMed Web of Science ®Google Scholar
• Xu N, Meisgen F, Butler LM, et al. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40. J Immunol. 2013;190(2):678–688. doi:10.4049/jimmunol.1202695
   PubMed Web of Science ®Google Scholar
• García-Rodríguez S, Arias-Santiago S, Blasco-Morente G, et al. Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity. J Eur Acad Dermatol Venereol. 2017;31(2):312–322. doi:10.1111/jdv.13861
   PubMed Web of Science ®Google Scholar
• Liu Q, Wu DH, Han L, et al. Roles of micro RNAs in psoriasis: immunological functions and potential biomarkers. Exp Dermatol. 2017;26(4):359–367. doi:10.1111/exd.13249
   PubMed Web of Science ®Google Scholar
• Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711–719. doi:10.1038/nchembio839
   PubMed Web of Science ®Google Scholar
• Desmet E, Van Gele M, Grine L, et al. Towards the development of a RNAi-based topical treatment for psoriasis: proof-of-concept in a 3D psoriasis skin model. Exp Dermatol. 2018;27(5):463–469. doi:10.1111/exd.13414
   PubMed Web of Science ®Google Scholar
• Mandal A, Kumbhojkar N, Reilly C, et al. Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations. Sci Adv. 2020;6(30):eabb6049. doi:10.1126/sciadv.abb6049
   PubMed Web of Science ®Google Scholar
• Budakoti M, Panwar AS, Molpa D, et al. Micro-RNA: the darkhorse of cancer. Cell Signal. 2021;83:109995. doi:10.1016/j.cellsig.2021.109995
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Nguyen GH, Fujita M, et al. MicroRNAs in Psoriasis. J Invest Dermatol. 2016;136(2):365–371. doi:10.1038/JID.2015.409
   PubMed Web of Science ®Google Scholar
• Fu D, Yu W, Li M, et al. MicroRNA-138 regulates the balance of Th1/Th2 via targeting RUNX3 in psoriasis. Immunol Lett. 2015;166(1):55–62. doi:10.1016/j.imlet.2015.05.014
   PubMed Web of Science ®Google Scholar
• Meisgen F, Xu N, Wei T, et al. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol. 2012;21(4):312–314. doi:10.1111/j.1600-0625.2012.01462.x
   PubMed Web of Science ®Google Scholar
• Wu R, Zeng J, Yuan J, et al. MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. J Clin Invest. 2018;128(6):2551–2568. doi:10.1172/JCI97426
   PubMed Web of Science ®Google Scholar
• Rapalli VK, Singhvi G, Dubey SK, et al. Emerging landscape in psoriasis management: from topical application to targeting biomolecules. Biomed Pharmacother. 2018;106:707–713. doi:10.1016/j.biopha.2018.06.136
   PubMed Web of Science ®Google Scholar
• Yang Z, Zeng B, Tang X, et al. MicroRNA-146a and miR-99a are potential biomarkers for disease activity and clinical efficacy assessment in psoriasis patients treated with traditional Chinese medicine. J Ethnopharmacol. 2016;194:727–732. doi:10.1016/j.jep.2016.08.028
   PubMed Web of Science ®Google Scholar
• Zhang W, Yi X, Guo S, et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study. J Cell Mol Med. 2014;18(11):2225–2234. doi:10.1111/jcmm.12359
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Perricone C, D’Antonio A, et al. Genetics, epigenetics, and gender impact in axial-spondyloarthritis susceptibility: an update on genetic polymorphisms and their sex related associations. Front Genet. 2021;12:671976. doi:10.3389/fgene.2021.671976
   PubMed Web of Science ®Google Scholar
• van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836–5845. doi:10.4049/jimmunol.0802999
   PubMed Web of Science ®Google Scholar
• Wu R, Li X, Li S, et al. Decreased microRNA-126 expression in psoriatic CD4 + T cells promotes T-helper 17 cell differentiation and the formation of dermatitis in imiquimod-induced psoriasis-like mice. J Dermatol. 2022;49(4):432–440. doi:10.1111/1346-8138.16272
   PubMed Web of Science ®Google Scholar
• Yan JJ, Qiao M, Li RH, et al. Downregulation of miR-145-5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis. Br J Dermatol. 2019;180(2):365–372. doi:10.1111/bjd.17256
   PubMed Web of Science ®Google Scholar
• Srivastava A, Nikamo P, Lohcharoenkal W, et al. MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis. J Allergy Clin Immunol. 2017;139(2):550–561. doi:10.1016/j.jaci.2016.07.025
   PubMed Web of Science ®Google Scholar
• Hermann H, Runnel T, Aab A, et al. MiR-146b probably assists miRNA-146a in the suppression of keratinocyte proliferation and inflammatory responses in psoriasis. J Invest Dermatol. 2017;137(9):1945–1954. doi:10.1016/j.jid.2017.05.012
   PubMed Web of Science ®Google Scholar
• Meng Y, Li J, Ye Z, et al. MicroRNA-148a facilitates inflammatory dendritic cell differentiation and autoimmunity by targeting MAFB. JCI Insight. 2020;5(8):e133721. doi:10.1172/jci.insight.133721
   PubMed Web of Science ®Google Scholar
• Srivastava A, Luo L, Lohcharoenkal W, et al. Cross-talk between IFN-γ and TWEAK through miR-149 amplifies skin inflammation in psoriasis. J Allergy Clin Immunol. 2021;147(6):2225‒2235.
   Web of Science ®Google Scholar
• Guo W, Xu F, Zhuang Z, et al. Ebosin ameliorates psoriasis-like inflammation of mice via miR-155 targeting tnfaip3 on IL-17 pathway. Front Immunol. 2021;12:662362. doi:10.3389/fimmu.2021.662362
   PubMed Web of Science ®Google Scholar
• Huang C, Zhong W, Ren X, et al. MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes. Cell Death Dis. 2021;12(11):963. doi:10.1038/s41419-021-04230-5
   PubMed Web of Science ®Google Scholar
• Xue Y, Liu Y, Bian X, et al. MiR-205-5p inhibits psoriasis-associated proliferation and angiogenesis: wnt/β-catenin and mitogen-activated protein kinase signaling pathway are involved. J Dermatol. 2020;47(8):882–892. doi:10.1111/1346-8138.15370
   PubMed Web of Science ®Google Scholar
• Feng H, Wu R, Zhang S, et al. Topical administration of nanocarrier miRNA-210 antisense ameliorates imiquimod-induced psoriasis-like dermatitis in mice. J Dermatol. 2020;47(2):147–154. doi:10.1111/1346-8138.15149
   PubMed Web of Science ®Google Scholar
• Abdallah F, Henriet E, Suet A, et al. MiR-21-3p/IL-22 axes are major drivers of psoriasis pathogenesis by modulating keratinocytes proliferation-survival balance and inflammatory response. Cells. 2021;10(10):2547. doi:10.3390/cells10102547
   PubMed Web of Science ®Google Scholar
• Liu A, Zhang B, Zhao W, et al. MicroRNA-215-5p inhibits the proliferation of keratinocytes and alleviates psoriasis-like inflammation by negatively regulating DYRK1A and its downstream signalling pathways. Exp Dermatol. 2021;30(7):932‒942.
   Web of Science ®Google Scholar
• Bian J, Liu R, Fan T, et al. miR-340 alleviates psoriasis in mice through direct targeting of IL-17A. J Immunol. 2018;201(5):1412–1420. doi:10.4049/jimmunol.1800189
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu L, Bian C, et al. MicroRNA let-7b inhibits keratinocyte differentiation by targeting IL-6 mediated ERK signaling in psoriasis. Cell Commun Signal. 2018;16(1):58. doi:10.1186/s12964-018-0271-9
   PubMedGoogle Scholar
• Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016;48(4):398–406. doi:10.1038/ng.3525
   PubMed Web of Science ®Google Scholar
• Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006–1014. doi:10.1038/ng.2359
   PubMed Web of Science ®Google Scholar
• Han G, Williams CA, Salter K, et al. A role for TGFbeta signaling in the pathogenesis of psoriasis. J Invest Dermatol. 2010;130(2):371–377. doi:10.1038/jid.2009.252
   PubMed Web of Science ®Google Scholar
• Li AG, Wang D, Feng XH, et al. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J. 2004;23(8):1770–1781. doi:10.1038/sj.emboj.7600183
   PubMed Web of Science ®Google Scholar
• Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9(6):650–657. doi:10.1038/ni.1613
   PubMed Web of Science ®Google Scholar
• Singh TP, Schön MP, Wallbrecht K, et al. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One. 2013;8(1):e51752.
   PubMed Web of Science ®Google Scholar
• Mao CM, Yang X, Cheng X, et al. Establishment of keratinocyte-specific Cre recombinase transgenic mice. Yi Chuan Xue Bao. 2003;30(5):407–413.
   PubMedGoogle Scholar
• Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17(3):375–387. doi:10.1016/S1074-7613(02)00391-6
   PubMed Web of Science ®Google Scholar
• Meng Z, Lu M. RNA Interference-induced innate immunity, off-target effect, or immune adjuvant? Front Immunol. 2017;8:331. doi:10.3389/fimmu.2017.00331
   PubMed Web of Science ®Google Scholar
• Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437(7057):369–375. doi:10.1038/nature03963
   PubMed Web of Science ®Google Scholar
• Traber GM, Yu AM. RNAi-based therapeutics and novel RNA bioengineering technologies. J Pharmacol Exp Ther. 2023;384(1):133–154. doi:10.1124/jpet.122.001234
   PubMed Web of Science ®Google Scholar
• Li Z, Rana TM. Molecular mechanisms of RNA-triggered gene silencing machineries. Acc Chem Res. 2012;45(7):1122–1131. doi:10.1021/ar200253u
   PubMed Web of Science ®Google Scholar
• Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A. 2001;98(17):9742–9747. doi:10.1073/pnas.171251798
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494‒498. doi:10.1038/35078107
   PubMed Web of Science ®Google Scholar
• McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature. 2002;418(6893):38‒39. doi:10.1038/418038a
   PubMed Web of Science ®Google Scholar
• Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296(5567):550‒553. doi:10.1126/science.1068999
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med. 2005;11(4):423–428. doi:10.1038/nm1207
   PubMed Web of Science ®Google Scholar
• Fan T, Wang S, Yu L, et al. Treating psoriasis by targeting its susceptibility gene Rel. Clin Immunol. 2016;165:47–54. doi:10.1016/j.clim.2016.03.009
   PubMed Web of Science ®Google Scholar
• Hsieh WL, Huang YH, Wang TM, et al. IFI27, a novel epidermal growth factor-stabilized protein, is functionally involved in proliferation and cell cycling of human epidermal keratinocytes. Cell Prolif. 2015;48(2):187–197. doi:10.1111/cpr.12168
   PubMed Web of Science ®Google Scholar
• Xiao CY, Zhu ZL, Zhang C, et al. Small interfering RNA targeting of keratin 17 reduces inflammation in imiquimod-induced psoriasis-like dermatitis. Chin Med J. 2020;133(24):2910–2918. doi:10.1097/CM9.0000000000001197
   PubMed Web of Science ®Google Scholar
• Luan C, Chen X, Zhu Y, et al. Potentiation of psoriasis-like inflammation by PCSK9. J Invest Dermatol. 2019;139(4):859‒867. doi:10.1016/j.jid.2018.07.046
   PubMed Web of Science ®Google Scholar
• Gao Y, Lu J, Bao X, et al. Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation. Exp Biol Med. 2021;246(11):1253–1262. doi:10.1177/1535370221993424
   Web of Science ®Google Scholar
• Chen Y, Yan H, Song Z, et al. Downregulation of TNIP1 expression leads to increased proliferation of human keratinocytes and severer psoriasis-like conditions in an imiquimod-induced mouse model of dermatitis. PLoS One. 2015;10(6):e0127957.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang T, Zhang C, et al. Upregulated E3 ligase tripartite motif-containing protein 21 in psoriatic epidermis ubiquitylates nuclear factor-κB p65 subunit and promotes inflammation in keratinocytes. Br J Dermatol. 2021;184(1):111–122. doi:10.1111/bjd.19057
   PubMed Web of Science ®Google Scholar
• Jakobsen M, Stenderup K, Rosada C, et al. Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. Mol Ther. 2009;17(10):1743–1753. doi:10.1038/mt.2009.141
   PubMed Web of Science ®Google Scholar
• Bracke S, Carretero M, Guerrero-Aspizua S, et al. Targeted silencing of DEFB 4 in a bioengineered skin-humanized mouse model for psoriasis: development of si RNA SEC osome-based novel therapies. Exp Dermatol. 2014;23(3):199–201. doi:10.1111/exd.12321
   PubMed Web of Science ®Google Scholar
• Johansen C, Funding AT, Otkjaer K, et al. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol. 2006;176(3):1431–1438. doi:10.4049/jimmunol.176.3.1431
   PubMed Web of Science ®Google Scholar
• Dam TN, Kang S, Nickoloff BJ, et al. 1α,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol. 1999;113(6):1082–1089. doi:10.1046/j.1523-1747.1999.00811.x
   PubMed Web of Science ®Google Scholar
• Wang X, Sun J, Hu J, Slominski AT. IMQ Induced K14-VEGF mouse: a stable and long-term mouse model of psoriasis-like inflammation. PLoS One. 2015;10(12):e0145498. doi:10.1371/journal.pone.0145498
   PubMed Web of Science ®Google Scholar
• Mellett M, Meier B, Mohanan D, et al. CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo. J Invest Dermatol. 2018;138(9):2010–2023. doi:10.1016/j.jid.2018.03.1525
   PubMed Web of Science ®Google Scholar
• Wan T, Pan Q, Ping Y. Microneedle-assisted genome editing: a transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders. Sci Adv. 2021;7(11):eabe2888. doi:10.1126/sciadv.abe2888
   PubMed Web of Science ®Google Scholar
• Wolfram JA, Diaconu D, Hatala DA, et al. Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol. 2009;174(4):1443–1458. doi:10.2353/ajpath.2009.080858
   PubMed Web of Science ®Google Scholar
• Jin J, Xue N, Liu Y, et al. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharm Sin B. 2020;10(2):276–288. doi:10.1016/j.apsb.2019.11.006
   PubMed Web of Science ®Google Scholar
• Li Y, Golden JB, Camhi MI, et al. Protection from psoriasis-related thrombosis after inhibition of IL-23 or IL-17A. J Invest Dermatol. 2018;138:2.
   Web of Science ®Google Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122. doi:10.1016/S0140-6736(15)00149-X
   PubMed Web of Science ®Google Scholar
• Capon F. The Genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526. doi:10.3390/ijms18122526
   PubMed Web of Science ®Google Scholar
• Bhat P, Garibyan L. The potential of CRISPR-guided therapies in the dermatology clinic. JID Innov. 2022;2(2):100103. doi:10.1016/j.xjidi.2022.100103
   PubMedGoogle Scholar
• D’Adamio S, Silvaggio D, Lombardo P, et al. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Expert Opin Drug Saf. 2019;18(11):1031–1041. doi:10.1080/14740338.2019.1663168
   PubMed Web of Science ®Google Scholar
• Parab S, Doshi G. The experimental animal models in psoriasis research: a comprehensive review. Int Immunopharmacol. 2023;117:109897. doi:10.1016/j.intimp.2023.109897
   PubMed Web of Science ®Google Scholar
• Swindell WR, Johnston A, Carbajal S, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One. 2011;6(4):e18266. doi:10.1371/journal.pone.0018266
   PubMed Web of Science ®Google Scholar
• Garber K. Psoriasis: from bed to bench and back. Nat Biotechnol. 2011;29(7):563–566. doi:10.1038/nbt.1906
   PubMed Web of Science ®Google Scholar